Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengdu Olymvax BiopharmaceuticalsSHSE:688319 +2.21%76 Cyclically Adjusted PS Ratio is 33.39 as of Aug. 23, 2026, which is 34% above its 10-year median of 25.00. GuruFocus rates SHSE:688319 with a GF Score™ of 76/100 and a GF Value™ of ¥22.21 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 529 Biotechnology companies, Chengdu Olymvax Biopharmaceuticals ranks worse than 87.52% on this metric.
The historical rank and industry rank for Chengdu Olymvax Biopharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
SHSE:688319'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.35 Med: 25 Max: 45.02
Current: 33.37
During the past 13 years, Chengdu Olymvax Biopharmaceuticals's highest Cyclically Adjusted PS Ratio was 45.02. The lowest was 14.35. And the median was 25.00.
SHSE:688319's Cyclically Adjusted PS Ratio is ranked worse than 87.52% of 529
companies
in the Biotechnology industry
Industry Median: 6.05
vs SHSE:688319: 33.37
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Chengdu Olymvax Biopharmaceuticals's adjusted revenue per share data of for the fiscal year that ended in Dec25 was ¥1.737. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ¥0.90 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Chengdu Olymvax Biopharmaceuticals Cyclically Adjusted PS Ratio Related Terms
Chengdu Olymvax Biopharmaceuticals Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Olymvax Biopharmaceuticals Cyclically Adjusted PS Ratio Chart
SHSE:688319 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Chengdu Olymvax Biopharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Olymvax Biopharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Olymvax Biopharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Chengdu Olymvax Biopharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Chengdu Olymvax Biopharmaceuticals Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 33.39 mean?
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a Cyclically Adjusted PS Ratio of 33.39 as of Aug. 23, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. This is 34% above median its historical median of 25.00. Over the past decade, Chengdu Olymvax Biopharmaceuticals' Cyclically Adjusted PS Ratio has ranged from 14.35 to 45.02. According to the industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #463 out of 529 companies in the Biotechnology industry, placing it in the top 87.5%.
Is Chengdu Olymvax Biopharmaceuticals' Cyclically Adjusted PS Ratio too high?
Chengdu Olymvax Biopharmaceuticals' current Cyclically Adjusted PS Ratio of 33.39 is 34% above median its 10-year median of 25.00. Over the past 10 years, this metric has ranged from a low of 14.35 to a high of 45.02. The Biotechnology industry median Cyclically Adjusted PS Ratio is 6.05. Chengdu Olymvax Biopharmaceuticals' value of 33.39 is 451.9% above this industry median. Based on the distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #463 out of 529 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #463 out of 529 companies for Cyclically Adjusted PS Ratio. This places Chengdu Olymvax Biopharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 6.05. Chengdu Olymvax Biopharmaceuticals' value of 33.39 is 451.9% above this benchmark. Historically, Chengdu Olymvax Biopharmaceuticals' own Cyclically Adjusted PS Ratio has ranged from 14.35 to 45.02 over the past decade. While the company's 10-year median is 25.00 vs. the industry median of 6.05, Chengdu Olymvax Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 6.05, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Olymvax Biopharmaceuticals's current Cyclically Adjusted PS Ratio of 33.39 is 451.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 6.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Olymvax Biopharmaceuticals's current Cyclically Adjusted PS Ratio is 33.39, which is 34% above median its own 10-year median of 25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥22.21, compared to a current price of ¥30.05 — trading 35.3% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 33.39, which is 34% above median its 10-year median of 25.00 and 451.9% above the Biotechnology industry median of 6.05. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current Cyclically Adjusted PS Ratio is 33.39 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued.
The current stock price of ¥30.05 is trading 35.3% above its estimated GF Value™ of ¥22.21.
GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Significantly Overvalued.
Key valuation signals for SHSE:688319:
Cyclically Adjusted PS Ratio: 33.39 (34% above median its 10-year median of 25.00)
GF Value™: ¥22.21 vs. price of ¥30.05 (35.3% above fair value)
Industry Position: 451.9% above the Biotechnology median (#463 of 529)
No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
76GF Score
Get the complete analysis for SHSE:688319
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688319 has been successfully added to your 
